AFP

Home / Lab Tests / AFP

A B
1
 Test Code: 503 AFP (TUMOR MARKER)
2
 Performing Lab:  SMA Specialty Medical Lab
3
 Clinical Significance:  The Atellica IM AFP assay is not a screening test for cancer and must never be used as such. This test should not be used for interpretation of the Maternal Serum AFP. AFP testing is a safe and effective supplement to patient care when used as part of the overall management strategy for patients undergoing treatment for non-seminomatous testicular cancer or for patients being monitored after therapy is complete. Do not interpret serum AFP as absolute evidence of the presence of malignant disease. At time of presentation, patients with confirmed non-seminomatous testicular cancer may have serum AFP concentrations within the range observed in healthy individuals. Since elevated AFP levels are often found in patients with other malignant and non-malignant conditions, the physician should rule out all other conditions associated with elevated AFP levels prior to the use of the Atellica IM AFP values in non-seminomatous testicular cancer management. Conversely, low concentrations of AFP are not necessarily indicative of absence of disease, particularly post surgery or after chemotherapy. Testicular tumors that are histologically categorized as pure seminoma do not synthesize AFP. The Atellica IM AFP assay, as a useful adjunct in cancer management, is intended for the evaluation of non-seminomatous testicular cancer, or mixed tumors with non-seminomatous elements, but not for pure seminoma. Additionally, several histologic subtypes of non-seminoma either do not synthesize AFP (choriocarcinoma) or do so unpredictably (teratoma). Therefore, AFP levels should be used concurrently with other
diagnostic and clinical patient information.
4
 Notes Values obtained with different assay methodologies should not be used interchangeably
5
 Reference Ranges:  <8.9 ng/dL
6
 Preferred Specimen:  Serum collected in Serum Separator Tube or Red Top Tube
7
 Alternate Specimens: 
If a red-top tube is used, transfer separated serum to a plastic transport tube
8
 Minimum Volume:  2 mL
9
 Specimen Container:  Gel Barrier Tube (Serum Separator Tube); Red Top Tube; Plastic Transfer Tube
10
 Collection Separate serum from cells within 45 minutes of collection
11
 Transport Temperature:  Refrigerated
12
 Specimen Stability:  Refrigerated: 7 days
13
 Causes for Rejection Improper labeling; plasma; hemolyzed sample; grossly lipemic sample
14
 Methodology:  Chemiluminescent
15
 Setup Days:  Monday-Saturday
16
 Setup Times:  Every Shift
17
 Turnaround:  24 Hours
18
 CPT Code(s):  82040
19
 (The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.)
20
 Instrument SIEMENS Atellica IM

ComprehensiveDx Clear™

ComprehensiveDx Clear™
Test Code: 1248
Test Description ComprehensiveDx Clear is a comprehensive panel for hereditary breast, ovarian, uterine, colorectal, pancreatic, prostate and melanoma cancers.
Genes Tested GENE ASSOCIATED CANCER(S) SYNDROME
APC Colorectal, pancreatic and other Familial Adenomatous Polyposis syndrome, Gardner syndrome, and Turcot syndrome
ATM Breast, pancreatic Ataxia-telangiectasia (if both copies of the gene are mutated)
BAP1 Renal, melanoma, mesothelioma Familial Melanoma Cancer Syndrome
BARD1 Breast, ovarian
BMPR1A Colorectal, gastric, pancreatic Juvenile Polyposis syndrome
BRCA1 Breast, ovarian, pancreatic, prostate, male breast Hereditary Breast and Ovarian Cancer syndrome
BRCA2 Breast, ovarian, pancreatic, prostate, male breast, melanoma Hereditary Breast and Ovarian Cancer syndrome;
Fanconi anemia (if both copies of the gene are mutated)
BRIP1 Ovarian, breast Fanconi anemia (if both copies of the gene are mutated)
CDH1 Breast, gastric, colorectal Hereditary Diffuse Gastric Cancer
CDK4 Melanoma, pancreatic Familial Melanoma Cancer Syndrome
CDKN2A Melanoma, pancreatic Familial Melanoma Cancer Syndrome
CHEK2 Breast, colorectal
DICER1 Lung, kidney, thyroid, ovarian
EPCAM Colorectal, gastric, endometrial, ovarian Lynch (Hereditary non-polyposis colon cancer) syndrome
FANCC Breast Fanconi anemia (if both copies of the gene are mutated)
MRE11A Breast, ovarian Ataxia-telangiectasia-like Syndrome (if both copies of the gene are mutated)
MSH2 Colorectal, gastric, endometrial, ovarian Lynch (Hereditary non-polyposis colon cancer) syndrome
MSH6 Colorectal, endometrial Lynch (Hereditary non-polyposis colon cancer) syndrome
MUTYH Colorectal MUTYH-associated Polyposis syndrome
NBN Breast, melanoma, prostate Nijmegen breakage syndrome (if both copies of the gene are mutated)
PALB2 Breast, ovarian, pancreatic, male breast Fanconi anemia (if both copies of the gene are mutated)
PMS2 Colorectal, endometrial, gastric, ovarian Lynch (Hereditary non-polyposis colon cancer) syndrome
POLD1 Colorectal, endometrial Familial Adenomatous Polyposis syndrome
POLE Colorectal, gastrointestinal Familial Adenomatous Polyposis syndrome
PTEN Breast, uterine, colorectal, thyroid, kidney, melanoma Cowden Syndrome / PTEN Hamartoma Tumor Syndrome
RAD50 Ovarian
RAD51C Breast, ovarian Fanconi anemia (if both copies of the gene are mutated)
RAD51D Breast, ovarian
SDHA Gastrointestinal, other Paragangliomas 5
SDHB Gastrointestinal, renal, other Paraganglioma and gastric stromal sarcoma
SDHC Gastrointestinal, renal, other Paraganglioma and gastric stromal sarcoma
SDHD Gastrointestinal, renal, other Cowden Syndrome 3; Paraganglioma and gastric stromal sarcoma
SMAD4 Colorectal, gastric Juvenile Polyposis syndrome
STK11 Colorectal, endometrial, gastric, ovarian, breast, pancreatic Peutz-Jeghers syndrome
TP53 Colorectal, breast, pancreatic, sarcomas, gastrointestinal, adrenocortical, leukemia Li-Fraumeni syndrome
Specimen Requirements Blood (two 4ml EDTA tubes, lavender top) or Extracted DNA (3ug in EB buffer) or Buccal Swab or Saliva (kits available upon request)
Turnaround Time (TAT) 2-3 weeks

This will close in 0 seconds

BreastDx Clear™

BreastDx Clear™
Test Code: 1250
Test Description BreastDx Clear is a multi-gene test that analyzes 16 breast cancer susceptibility genes. Although all women have some risk of developing breast and/or ovarian cancer at some point in their lives, having a mutation in one of the breast cancer susceptibility genes increases this risk. Men who have a mutation in one of the breast cancer susceptibility genes have an increased risk of breast, prostate, pancreatic, gastric and other cancer types.
Genes Tested GENE ASSOCIATED CANCER(S) SYNDROME
ATM Breast, pancreatic Ataxia-telangiectasia (if both copies of the gene are mutated)
BARD1 Breast, ovarian
BRCA1 Breast, ovarian, pancreatic, prostate, male breast Hereditary Breast and Ovarian Cancer syndrome
BRCA2 Breast, ovarian, pancreatic, prostate, male breast, melanoma Hereditary Breast and Ovarian Cancer syndrome;
Fanconi anemia (if both copies of the gene are mutated)
BRIP1 Ovarian, breast Fanconi anemia (if both copies of the gene are mutated)
CDH1 Breast, gastric, colorectal Hereditary Diffuse Gastric Cancer
CHEK2 Breast, colorectal
FANCC Breast Fanconi anemia (if both copies of the gene are mutated)
MRE11A Ovarian, breast Ataxia-telangiectasia-like Syndrome (if both copies of the gene are mutated)
NBN Breast, melanoma, prostate Nijmegen breakage syndrome (if both copies of the gene are mutated)
PALB2 Breast, ovarian, pancreatic, male breast Fanconi anemia (if both copies of the gene are mutated)
PTEN Breast, uterine, colorectal, thyroid, kidney Cowden Syndrome / PTEN Hamartoma Tumor Syndrome
RAD51C Breast, ovarian Fanconi anemia (if both copies of the gene are mutated)
RAD51D Breast, ovarian
STK11 Breast, ovarian, colorectal, gastric, pancreatic Peutz-Jeghers Syndrome
TP53 Breast, brain, sarcomas, gastrointestinal, adrenocortical, leukemia Li-Fraumeni Syndrome
Specimen Requirements Blood (two 4ml EDTA tubes, lavender top) or Extracted DNA (3ug in EB buffer) or Buccal Swab or Saliva (kits available upon request)
Turnaround Time (TAT) 2-3 weeks

This will close in 0 seconds

ColoDx Clear™

ColoDx Clear™
Test Code: 1251
Test Description Colorectal cancer is the fourth most common type of cancer diagnosed in the United States and the second leading cause of cancer-related deaths in the country.
ColoDx Clear is a multi-gene test focused on hereditary colon cancer syndromes. Pathogenic variants (mutations) in high-risk colorectal cancer genes are associated with several hereditary cancer syndromes and increase the risk of cancer in many organs.
Genes Tested GENE ASSOCIATED CANCER(S) SYNDROME
APC Colorectal, pancreatic and other Familial Adenomatous Polyposis syndrome, Gardner syndrome, and Turcot syndrome
BMPR1A Colorectal, gastric Juvenile Polyposis syndrome
EPCAM Colorectal, gastric, endometrial, ovarian Lynch (Hereditary non-polyposis colon cancer) syndrome
MLH1 Colorectal, gastric, endometrial, ovarian Lynch (Hereditary non-polyposis colon cancer) syndrome
MSH2 Colorectal, gastric, endometrial, ovarian Lynch (Hereditary non-polyposis colon cancer) syndrome
MSH6 Colorectal, endometrial Lynch (Hereditary non-polyposis colon cancer) syndrome
MUTYH Colorectal MUTYH-associated Polyposis syndrome
PMS2 Colorectal, endometrial, gastric, ovarian Lynch (Hereditary non-polyposis colon cancer) syndrome
POLD1 Colorectal, endometrial Familial Adenomatous Polyposis syndrome
POLE Colorectal, gastrointestinal Familial Adenomatous Polyposis syndrome
PTEN Colorectal, endometrial, breast, melanoma Cowden syndrome
SMAD4 Colorectal, gastric Juvenile Polyposis syndrome
STK11 Colorectal, endometrial, gastric, ovarian, breast, pancreatic Peutz-Jeghers syndrome
TP53 Colorectal, breast, pancreatic and other Li-Fraumeni syndrome
Specimen Requirements Blood (two 4ml EDTA tubes, lavender top) or Extracted DNA (3ug in EB buffer) or Buccal Swab or Saliva (kits available upon request)
Turnaround Time (TAT) 2-3 weeks

This will close in 0 seconds

ProstateDx Clear™

ProstateDx Clear™
Test Code: 1257
Test Description: The ProstateDx Clear™  Panel examines genes associated with an increased risk for prostate cancer.  This test includes both well-established prostate cancer susceptibility genes, as well as candidate genes with limited evidence of an association with prostate cancer.
Genes Tested: ATM, BRCA1, BRCA2, CHEK2, EPCAM, HOXB13, MLH1, MSH2, MSH6,
NBN, PALB2, PMS2, TP53
Specimen Requirements Blood (two 4ml EDTA tubes, lavender top) or Extracted DNA (3ug in EB buffer)
or Buccal Swab or Saliva (kits available upon request)
Turnaround Time (TAT) 2-3 weeks

This will close in 0 seconds